Shares in biotech Equillium (EQ) have almost tripled in Monday’s pre-market trading after the company announced that a clinical trial conducted in India by its partner Biocon demonstrated that itolizumab significantly reduced mortality in patients hospitalized with COVID-19.Equillium is currently developing itolizumab to treat severe autoimmune and inflammatory disorders. The stock is currently trading up 260% in the pre-market.Biocon also announced that the Drugs Controller General of India (DCGI) has granted restricted emergency use of itolizumab for the treatment of cytokine release syndrome (CRS) in COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) in India.Based on the encouraging topline results and DCGI approval, Equillium revealed that it is now planning to conduct a global randomized controlled clinical trial of itolizumab in COVID-19 patients for which it will file a U.S. investigational new drug application (IND).Biocon conducted a randomized, controlled, open-label study at four hospitals in India, enrolling a total of 30 hospitalized COVID-19 patients with moderate to severe ARDS. Twenty patients were randomized to receive itolizumab plus best supportive care, while 10 patients received best supportive care alone. The primary endpoint was mortality at one month.As reported by Biocon: * In the itolizumab arm there were no deaths and all patients have recovered; in the control arm three patients died and the remainder have recovered * The mortality benefit observed in the itolizumab arm was statistically significant * Consistent with the observed clinical improvement, patients who received itolizumab also experienced significant reductions in inflammatory cytokines“The results of this clinical trial reported by Biocon are encouraging and support the hypothesis that itolizumab’s novel immune-modulating mechanism may have promise in addressing the severe immuno-inflammatory complications experienced by COVID-19 patients,” said Bruce Steel, CEO of Equillium.Itolizumab is a first-in-class immune-modulating antibody therapeutic with a novel mechanism of action that inhibits the activity and trafficking of pathogenic T cells that release pro-inflammatory cytokines in a range of autoimmune and inflammatory diseases. Equillium acquired rights to develop and commercialize itolizumab in the U.S., Canada, Australia and New Zealand through an exclusive collaboration and license agreement with Biocon.Equillium is currently evaluating itolizumab under two open U.S. INDs for the treatment of acute graft-versus-host disease and lupus nephritis, as well as conducting a clinical study in uncontrolled asthma in Australia and New Zealand.In March due to the emerging COVID-19 pandemic, Equillium announced that it was pausing enrollment in the EQUIP trial for uncontrolled asthma and the EQUALISE trial for lupus nephritis. Equillium has now announced that patient enrollment in both these studies has resumed.Two analysts have recently published buy ratings on EQ. That’s with an average price target of $12. Stifel Nicolaus analyst Derek Archila reiterated his buy rating on the stock following the latest news.“We note the trial in hospitalized COVID-19 patients was small (n=30), open-label and on top of standard of care, and little data were shared but according the Biocon/EQ press releases, the itolizumab arm did demonstrate a statistically significant benefit on mortality at one-month (the primary endpoint)” he told investors.The current literature suggests approximately ~8% of COVID-19 patients develop ARDS and if itolizumab were to be priced in line with Gilead’s (GILD) remdesivir (~$2,500-$3,000 per course) this could be a meaningful market opportunity for EQ, Archila added. (See EQ stock analysis on TipRanks).Related News: Australia Provisionally Approves Gilead’s Covid-19 Treatment Gilead Reveals Covid-19 Treatment Remdesivir Reduces Mortality Risk Moderna Inks Deal With Rovi To Supply Potential Covid-19 Vaccine Outside US More recent articles from Smarter Analyst: * Disney World Reopens To Small Numbers, Analyst Optimistic On Outlook * Alibaba Co-Founder Jack Ma Reduces Stake To 4.8% * South Korea: 1 in 3 Covid-19 Patients Improved With Gilead’s Remdesivir * Amgen Pours A Further $421M Into China’s BeiGene
from Yahoo Finance https://ift.tt/32fNR1E
Yahoo Finance’s Emily McCormick breaks down Pepsico’s second quarter earnings report. In addition, McCormick breaks down the details of a recent deal in the chipmaker sector, Analog Devices’s purchase of Maxim Integrated in an all-stock deal. 
Yahoo Finance’s Alexis Christoforous and Brian Sozzi speak with Rethink Impact Founder & Managing Partner, Jenny Abramson, about the firm’s successful second round of funding, and diversifying the venture capital space.What are the early trends we should look for to identify a stock that could multiply in value over the long term…
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
Jul.13 — New York City Mayor Bill de Blasio led a group that painted a Black Lives Matter mural in bold yellow letters on 5th Avenue in front of Trump Tower on July 9. Similar murals have been painted on streets around the country.
Jul.13 — President Donald Trump issued a commutation for the prison sentence of Roger Stone late Friday. Stone was convicted of witness tampering and lying to Congress during the Russian election interference investigation. Stone is a political operative and long-time ally of Trump. Stone spoke to reporters in Florida on Saturday.The candidates, BNT162b1 and BNT162b2, are the most advanced of the at least four vaccines being assessed by the companies in ongoing trials in the United States and Germany. Pfizer’s shares were up about 2% and U.S.-listed shares of BioNTech were up about 6% before the bell. Earlier this month, the companies said BNT162b1 showed potential against the virus and was found to be well tolerated in early-stage human trials.